Fig. 2.

Monthly injections of GSK744 LA protect rhesus macaques against three intravaginal SHIV challenges. (A) Study design. Twelve female rhesus macaques were injected IM with 30 mg of Depo-Provera on weeks -3 and 2. Eight rhesus macaques were injected IM in the quadriceps with 50 mg/kg of GSK744 LA at two time points, weeks 0 and 4. Four Depo-treated rhesus macaques served as controls. All animals were challenged intravaginally on week 1 with 300 TCID₅₀ of SHIV162P3. GSK744 LA-treated rhesus macaques were further challenged on weeks 5 and 7. All rhesus macaques were followed for 24 weeks. (B) Kaplan-Meier plot of GSK744 LA-treated and control rhesus macaques remaining aviremic following three intravaginal SHIV challenges. (C) Viral loads of control rhesus macaques (in grey) and GSK744 LA-treated rhesus macaques (in color). Open symbols represent samples sequenced for the integrase-coding region. Dotted line represents the LOQ, >40 SHIV RNA copies/mL plasma. (D) Plasma PK of individual GSK744 LA-treated rhesus macaques throughout the study. Open symbols represent drug concentrations at the time of first viral RNA detection. Dotted and dashed horizontal lines represent 1x and 4x PAIC₉₀, respectively. LOQ >0.01 μg/mL